Insys Therapeutics (INSY) Misses Q3 EPS

Insys Therapeutics (NASDAQ: INSY) reported Q3 EPS of ($0.41), $0.20 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $18.3 million versus the consensus estimate of $23.52 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Benchmark Reiterates Buy Rating on Odysight.AI Inc. (ODYS)
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30